EPITHELIX

Evaluation of anti-inflammatory effect of compounds through systemic or airborne delivery on fully differentiated human airway epithelia (MucilAir™)

Aim:

The aim of this assay is to evaluate and rank the anti-inflammatory effect of compounds through systemic or airborne delivery.

Airborne delivery

Model:

The inflamed condition of the airway epithelium is mimicked by stimulating MucilAir with known pro-inflammatory mediators such as LPS or 10% fetal bovine serum.

Endpoint Analysis:

The anti-inflammatory effect is monitored by IL-8 release: First, MucilAir is incubated with LPS or TNF-α or FBS 10% in culture medium. Test compound is next added to the apical (to mimic airborne dlivery) or at the basolateral side (to mimic systemic exposure) of MucilAir.

Anti inflammatory effect
x Anti inflammatory effect

Dose and time dependent anti-inflammatory effect of Mometasone Furoate upon stimulation with 10% FBS:

Ctrl-: vehicle control (0.9% NaCl); ctrl+: 10% FBS; 25 and 100 μg/ml of Mometasone Furoate in culture medium was applied to the baso-lateral compartment.

More information: Please contact